Clinical trial CONTACT 02
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer
Cancers | |
---|---|
Organ | prostate |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Exelixis |
EudraCT Identifier | 2020-000348-77 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04446117 |
Last update |